Smith & Nephew plc (LON:SN) had its price objective lifted by investment analysts at J P Morgan Chase & Co from GBX 1,361 ($17.96) to GBX 1,382 ($18.24) in a report issued on Thursday, October 19th, MarketBeat Ratings reports. The firm currently has a “neutral” rating on the stock. J P Morgan Chase & Co’s target price suggests a potential downside of 3.22% from the stock’s current price.
A number of other analysts have also issued reports on SN. Deutsche Bank AG reaffirmed a “hold” rating and issued a GBX 1,200 ($15.84) price target on shares of Smith & Nephew plc in a research note on Friday, July 28th. Citigroup Inc. reaffirmed a “sell” rating and issued a GBX 1,160 ($15.31) price target on shares of Smith & Nephew plc in a research note on Thursday, October 12th. Credit Suisse Group reaffirmed a “neutral” rating and issued a GBX 1,200 ($15.84) price target on shares of Smith & Nephew plc in a research note on Thursday, July 20th. Jefferies Group LLC lifted their price objective on Smith & Nephew plc from GBX 1,350 ($17.81) to GBX 1,515 ($19.99) and gave the stock a “buy” rating in a research report on Friday, July 28th. Finally, Goldman Sachs Group, Inc. (The) restated a “neutral” rating and issued a GBX 1,380 ($18.21) target price on shares of Smith & Nephew plc in a research report on Monday, September 11th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of GBX 1,300.58 ($17.16).
Smith & Nephew plc (LON SN) opened at 1428.00 on Thursday. The company’s 50-day moving average is GBX 1,378.08 and its 200 day moving average is GBX 1,341.74. Smith & Nephew plc has a 52-week low of GBX 1,064.91 and a 52-week high of GBX 1,442.00. The company’s market cap is GBX 12.50 billion.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/28/smith-nephew-plc-sn-pt-raised-to-gbx-1382-at-j-p-morgan-chase-co.html.
In related news, insider Virginia Bottomley bought 223 shares of the stock in a transaction that occurred on Wednesday, August 16th. The stock was purchased at an average cost of GBX 1,380 ($18.21) per share, with a total value of £3,077.40 ($4,060.97).
About Smith & Nephew plc
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with MarketBeat.com's FREE daily email newsletter.